Gemcitabine, a rare cause of chemotherapy-related reticulate hyperpigmentation.

Dermatol Reports

Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC).

Published: September 2024

AI Article Synopsis

Article Abstract

Reticulate pigmentary disorders can be classified into inherited or acquired and cutaneous drug- induced reticulate hyperpigmentation belongs to this last group. The list of the drugs involved is constantly increasing and chemotherapy agents are frequently implicated. We report a new case of chemotherapy-related reticulate hyperpigmentation to gemcitabine, even though a previous chemotherapy with nanoparticle, albumin-bound (Nab®) paclitaxel and gemcitabine may have promoted the onset of the disease. Reassurance of the patients is important in these cases, in order to continue the chemotherapy, and gradual fading of the hyperpigmentation is usually observed, as in our case.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11582954PMC
http://dx.doi.org/10.4081/dr.2024.9872DOI Listing

Publication Analysis

Top Keywords

reticulate hyperpigmentation
12
chemotherapy-related reticulate
8
gemcitabine rare
4
rare chemotherapy-related
4
reticulate
4
hyperpigmentation
4
hyperpigmentation reticulate
4
reticulate pigmentary
4
pigmentary disorders
4
disorders classified
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!